Evaluation of Clarity Ultrasound Guidance for Prostate Therapy

NCT02388308 | Completed

• 1 other identifier: 4267
• Study Type: observational
• Target: 61
• Locations: 1 country
• Sites: 1

Brief Summary

Radiotherapy (RT) is an important treatment for prostate cancer with over 10,000 men receiving RT per year in the UK. Prostate RT aims to deliver radiation dose to the prostate to kill cancer cells whilst minimizing the dose given to surrounding normal tissues, such as the bladder or the rectum. Radiation is delivered in a number of daily treatments which are called 'fractions'. The position of the prostate varies each day and during the radiation delivery. To accurately aim the radiation the prostate needs to be located before daily treatment. Clarity is an ultrasound image guidance system that locates the prostate and monitors its position during treatment. Ultrasound does not give a radiation dose, is non-invasive, provides fast imaging and can easily visualise soft tissues. Before Clarity is implemented the investigators wish to ensure that it can accurately locate and monitor the prostate by comparing Clarity with marker-based techniques in 24 patients. Patients receive markers as part of other trials which are currently recruiting at The Royal Marsden (for example, patients in the DELINEATE trial and the PACE trials receive implanted gold markers and patients in the PROSPARE trial have received electromagnetic markers). Patients who have received or will be receiving markers as part of other studies will be asked to also to take part in this study. This means that there will be no additional intervention for patients as a result of this study. Clarity will be considered a safe and effective imaging system if the mean and standard deviation of the differences between Clarity measurements and marker measurements, of prostate position, are less than 1mm. It is possible that markers will influence the Clarity measurements. To find out if this happens, the mean and standard deviation of Clarity measurements in a group of 24 patients without markers to the group with markers will be compared. Primary Aim: To evaluate the accuracy of Clarity ultrasound image guidance system for prostate motion estimation during treatment (intra-fraction), by comparison with implanted marker-based image guidance techniques. Primary Hypothesis: Clarity can be safely used to deliver radiotherapy using similar (within 1mm) treatment margins to those that would be employed if fiducial markers based image guidance techniques were used.

Conditions

Prostate Cancer

Keywords

Prostate cancer; Image-guided radiotherapy; Ultrasound guidance

Outcome Measures

Primary Outcomes (1)

• Prostate position (measured in millimeters) measured using Clarity ultrasound and implanted fiducial markers

  Mean (and standard deviation) of the differences in prostate position determined using Clarity and that determined using fiducial marker based image guidance during radiotherapy delivery.

  Outcome measures will be assessed for each patient during radiotherapy, an average of five weeks.

Study Arms (4)

Patient volunteers

Patients who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy including a CT scan.

Device: Clarity ultrasound

Gold fiducial marker group

Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.

Device: Clarity ultrasound

Electromagnetic marker group

Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion, or patients who have previously received RT for prostate cancer which included EM insertion.

Device: Clarity ultrasound

General patients

Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.

Device: Clarity ultrasound

Interventions

Clarity ultrasound DEVICE

Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.

Electromagnetic marker group; General patients; Gold fiducial marker group; Patient volunteers

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients undergoing radiotherapy for prostate cancer

You may qualify if:

• Two patient groups and two patient volunteer groups will be recruited:
• Groups 1: Patient volunteers who have received radiotherapy for prostate cancer which included a planning CT scan, or who are currently receiving radiotherapy.
• Groups 2 and 3:
• Patients receiving radiotherapy for prostate cancer as part of a clinical trial or standard care which includes gold FM or EM insertion
• Patients who have previously received RT for prostate cancer which included EM insertion.
• Group 4: Patients who are receiving radiotherapy for prostate cancer and who are not receiving FMs. Attempts will be made to match Group 4 patients BMI and time receiving hormone therapy to patients in group 2 and 3 (see below, section 6.1 recruitment.

You may not qualify if:

• Groups 1 to 4: Patients who have received prostatectomy.
• Groups 2 and 4: Patients receiving less than 6 RT fractions.
• Group 4 only: Patients who have received FMs or EMs.

Sponsors & Collaborators

• Institute of Cancer Research, United Kingdom: lead
• Royal Marsden NHS Foundation Trust: collaborator

Study Sites (1)

The Royal Marsden

Sutton, SM2 5PT, United Kingdom

Location

Related Publications (2)

• Grimwood A, Rivaz H, Zhou H, McNair HA, Jakubowski K, Bamber JC, Tree AC, Harris EJ. Improving 3D ultrasound prostate localisation in radiotherapy through increased automation of interfraction matching. Radiother Oncol. 2020 Aug;149:134-141. doi: 10.1016/j.radonc.2020.04.044. Epub 2020 May 6.

  PMID: 32387546 DERIVED

• Grimwood A, McNair HA, O'Shea TP, Gilroy S, Thomas K, Bamber JC, Tree AC, Harris EJ. In Vivo Validation of Elekta's Clarity Autoscan for Ultrasound-based Intrafraction Motion Estimation of the Prostate During Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):912-921. doi: 10.1016/j.ijrobp.2018.04.008. Epub 2018 Apr 16.

  PMID: 29859785 DERIVED

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Officials

• Emma Harris

  Institute of Cancer Research, United Kingdom

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 20, 2015
• First Posted: March 17, 2015
• Study Start: May 15, 2015
• Primary Completion: June 18, 2018
• Study Completion: June 18, 2018
• Last Updated: June 19, 2018

Record last verified: 2018-06

Locations

GB (1)